Should You Ditch GlaxoSmithKline plc And Buy Vectura Group PLC And SkyePharma PLC?

Are these 2 pharmaceutical stocks better buys that GlaxoSmithKline plc (LON: GSK)? Check out Vectura Group PLC (LON: VEC) and SkyePharma PLC (LON: SKP).

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

With the stock market having been akin to a rollercoaster ride so far in 2016, many investors are understandably seeking out defensive stocks. This makes sense because a volatile portfolio is never much fun and can lead to a great deal of worry and the potential for sleepless nights.

One stock that offers defensive characteristics is GlaxoSmithKline (LSE: GSK). Part of the reason for this is the fact that its profitability is less positively correlated to the performance of the global economy than is the case for most of its FTSE 100 peers. In other words, GlaxoSmithKline depends less on GDP growth and more on a strong drugs pipeline for its bottom-line growth. As such, even if there’s further volatility in share prices, GlaxoSmithKline could continue to outperform the FTSE 100, as it has done since the turn of the year, by over 5%.

In addition, GlaxoSmithKline also pays a superb dividend. It currently yields 5.8% and although dividends are due to flatline over the next couple of years as the company implements a major restructuring programme, its shareholder payouts remain relatively high and consistent. During a period of uncertainty this is a superb ally for nervous investors.

As well as defensive attributes, GlaxoSmithKline also has a strong pipeline of new drugs that have the potential to rapidly increase its sales and profit over the medium-to-long term. In fact, GlaxoSmithKline’s portfolio is one of the most diversified in the business and it has real potential to generate multiple blockbuster drugs, with its ViiV Health Care subsidiary being of key importance to the company’s long-term growth. And with its bottom line due to be positively impacted by cost cuts, GlaxoSmithKline seems to be an excellent buy for the long term.

What’s the alternative?

Of course, it’s not the only stock in the pharmaceutical sector that could be worth adding to your portfolio. In fact, there are a number of companies that offer tremendous forecast growth rates and yet trade on highly appealing valuations.

For example, airways diseases specialist Vectura (LSE: VEC) is forecast to increase its bottom line by 116% in the next financial year following what’s expected to be a profitable year in 2016. And with its shares trading on a price-to-earnings (P/E) ratio of 53, this equates to a price-to-earnings growth (PEG) ratio of only 0.5. This indicates that they could deliver improved performance following their fall of 8% in the last six months.

Similarly, drug delivery specialist SkyePharma (LSE: SKP) is due to post a rise in its bottom line of 51% in 2016. When combined with its P/E ratio of 25.6, this equates to a PEG ratio of only 0.5 and indicates that there’s considerable upside potential. As with Vectura, SkyePharma pays no dividend and isn’t expected to commence shareholder payouts this year. In addition, the two companies are much smaller than GlaxoSmithKline and arguably offer less defensive characteristics or stability, but do have greater growth potential.

As such, a mix of all three stocks seems to be a sound move, although for investors who are only able to buy one of the three companies, GlaxoSmithKline appears to have the perfect mix of growth, income and defensive qualities.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

US Stock

Here are the best-performing S&P 500 stocks after the US election result

Jon Smith notes some of the largest gainers from the S&P 500 yesterday and explains how the election result has…

Read more »

Growth Shares

2 UK stocks knocking on the door of promotion to the FTSE 100

Jon Smith points out a couple of UK stocks that he feels could be ready for the big league based…

Read more »

Investing Articles

Rolls-Royce shares just fell 7%. Is it time to buy?

This investor in Rolls-Royce shares takes a look at the FTSE 100 engine maker's trading update to see what caused…

Read more »

Young Black woman looking concerned while in front of her laptop
Investing Articles

What’s going on with the Auto Trader share price?

Paul Summers takes a closer look at why the Auto Trader share price has tumbled despite the company posting higher…

Read more »

Investing Articles

Legal & General shares look set to give me a mind-blowing 10.22% yield in 2026!

Harvey Jones is getting a brilliant second income from his Legal & General shares and expects even more to come.…

Read more »

Investing Articles

I’d consider this beaten-down FTSE 100 dividend stock to target a second income of £19,000

Our writer sees an opportunity to earn a substantial second income by investing in this UK insurance giant. Here’s his…

Read more »

Investing Articles

How cheap is the 72p Vodafone share price?

The Vodafone share price looks very cheap having fallen to a 72p price tag. But is it really the bargain…

Read more »

Aerial shot showing an aircraft shadow flying over an idyllic beach
Investing Articles

Up 43% in a year and the IAG share price could keep on rising!

One of the FTSE 100’s highest-flying stocks still looks cheap on an earnings basis. Is this a brilliant buy for…

Read more »